Itulazax (Betula Verrucosa (108))

Betula verrucosa in Itulazax provides controlled sublingual exposure to the birch pollen allergen. This repeated exposure shifts the immune response from an IgE‑driven allergy toward a more tolerant IgG4 profile and modulates T‑cell activity, thereby decreasing hypersensitivity over time.

The dosing regimen for Itulazax is determined by the prescribing physician based on the patient’s sensitivity, age, and clinical response. The prescriber will set the initial dose and any subsequent titration steps according to established allergy immunotherapy protocols.

Safety data for Itulazax in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To order Itulazax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Itulazax is a sublingual formulation, offering a non‑injectable route compared with traditional subcutaneous birch pollen extracts. This can improve patient convenience and adherence, while delivering comparable immunologic tolerance when administered under medical supervision.

Itulazax should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight. No refrigeration is required, but keep the container tightly closed to maintain stability.

Itulazax is administered sublingually. The patient places the prescribed dose under the tongue and holds it for the recommended time before swallowing, following the specific instructions provided by the prescribing clinician.

The most serious risks include systemic allergic reactions such as anaphylaxis, severe bronchospasm, and angioedema. Patients should be observed after the first dose and instructed to seek immediate medical attention if they experience any signs of a severe reaction.

Itulazax is contraindicated in individuals with a known hypersensitivity to Betula verrucosa extract, those with uncontrolled asthma, or patients who have experienced severe systemic reactions to previous allergen immunotherapy. A healthcare professional should evaluate suitability before prescribing.